Answers are grounded in this paper and cite their sources.
A systematic review examines no-fault compensation for vaccine injuries, highlighting its implications for public health policies.
The COVID-19 pandemic brought about a unique and rapid period of global vaccine innovation. It revealed structural challenges not only in global vaccine affordability and distribution but in the liability and indemnity structures that can both impede access and affect fair outcomes for the small number of people who suffer severe side effects. This review examines vaccine injury and compensation mechanisms, including no-fault compensation schemes, aimed at addressing both the liability and indemnity concerns of developers and the compensation due those suffering severe side effects. The ultimate aim of the review is to provide a classification of systems for those countries that are considering adopting NFCS as part of their broader public health readiness and preparedness strategies.
No takes yet. Share an insight, caveat, or question.
Halabi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: